Ironwood (IRWD) Pharmaceuticals announced that it received a notification letter on March 21, 2025 from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that, as a result of the Company’s delay in filing its Annual Report on Form 10-K for the year ended December 31, 2024 with the Securities and Exchange Commission, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires Nasdaq-listed companies to timely file all required periodic financial reports with the SEC.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRWD:
- Ironwood Pharma Delays 10-K Filing Due to Internal Issues
- Strategic Developments and NDA Enhancements Drive Buy Rating for Ironwood Pharma
- Ironwood Pharmaceuticals Reports 2024 Financial Results
- Ironwood Pharmaceuticals’ Earnings Call: Growth Amid Challenges
- Ironwood sees FY25 revenue $260M – $290M, consensus $287.62M